1-4 of 4
Björn Dahlöf
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Selectivity and Long Action of In Vivo Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Compared to FDA-Approved Prostacyclin Agonists Iloprost and Selexipag in the Prevention of Thrombosis

Livia Stanger, Mariane Flores, Krista A Goerger, Bjorn Dahlof, Michael Holinstat
Journal: Blood
Blood (2024) 144 (Supplement 1): 2544.
https://doi.org/10.1182/blood-2024-202456
Published: 2024
Journal Articles

HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding

Livia Stanger, Michael Holinstat, Sylviane Lambert, Pooja Yalavarthi, Niklas Bergh, Bjorn Dahlof
Journal: Blood
Blood (2023) 142 (Supplement 1): 1195.
https://doi.org/10.1182/blood-2023-186602
Published: 2023
Journal Articles

The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor

Livia Stanger, Adriana Yamaguchi, Pooja Yalavarthi, Sylviane Lambert, Devin Gilmore, Andrew Rickenberg, Catherine Luke, Kiran Kumar, Andrea T. Obi, Andrew White, Niklas Bergh, Björn Dahlöf, Michael Holinstat
Journal: Blood
Blood (2023) 142 (18): 1556–1569.
https://doi.org/10.1182/blood.2023020622
Published: 2023
Includes: Supplemental data
Journal Articles

CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists

Livia Stanger, Pooja Yalavarthi, Sylviane Lambert, Andrew Rickenberg, Krista Goerger, Devin Gilmore, Bjorn Dahlof, Niklas Bergh, Michael Holinstat
Journal: Blood
Blood (2023) 142 (Supplement 1): 1188.
https://doi.org/10.1182/blood-2023-186300
Published: 2023